Corey Cutler, MD, MPH, on MDS: Evaluating Treatments in Older Patients With Advanced Disease

December 05, 2020 By The ASCO Post Staff

Corey Cutler, MD, MPH, of Dana-Farber Cancer Institute, discusses results from a multicenter trial that compared reduced-intensity allogeneic hematopoietic cell transplantation to hypomethylating therapy or best supportive care in patients aged 50 to 75 with advanced myelodysplastic syndromes (Abstract 75).

Related Content